← Edwards Lifesciences Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $3.0b |
$3.4b
+15.91%
|
$3.7b
+8.37%
|
$4.3b
+16.79%
|
$4.4b
+0.88%
|
$5.2b
+19.29%
|
$5.4b
+2.86%
|
$6.0b
+11.56%
|
$5.4b
-9.41%
|
$6.1b
+11.55%
|
$6.5b
+7.33%
|
|
| Cost of Revenue | $797.4m |
$875.3m
+9.77%
|
$939.4m
+7.32%
|
$1.1b
+18.63%
|
$1.1b
-3.03%
|
$1.2b
+15.57%
|
$1.1b
-13.49%
|
$1.4b
+27.71%
|
$1.1b
-19.01%
|
$1.3b
+19.39%
|
$1.4b
+8.17%
|
|
| Gross Profit | $2.2b |
$2.6b
+18.17%
|
$2.8b
+8.73%
|
$3.2b
+16.17%
|
$3.3b
+2.23%
|
$4.0b
+20.51%
|
$4.3b
+7.99%
|
$4.6b
+7.51%
|
$4.3b
-6.55%
|
$4.7b
+9.52%
|
$5.1b
+7.09%
|
|
| Interest Income (Expense), Net | — | — | ($29.9m) | — | — | — | — | — | ($19.8m) |
($20.4m)
-3.03%
|
$158.4m
+876.47%
|
|
| Research and Development Expense | $443.3m | $552.6m | $622.2m | $752.7m | $760.7m | $903.1m | $945.2m | $1.1b | $1.1b | $1.1b | $1.1b | |
| Selling, General and Administrative Expense | $904.7m | $984.7m | $1.1b | $1.2b | $1.2b | $1.5b | $1.6b | $1.8b | $1.8b | $2.1b | $2.2b | |
| Amortization of Intangible Assets | $7.6m | $7.8m | $2.5m | $4.6m | $5.4m | $7.7m | $5.7m | $6.1m | $5.6m | $8.4m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $751.2m |
$1.1b
+45.02%
|
$748.2m
-31.32%
|
$1.1b
+53.27%
|
$897.6m
-21.73%
|
$1.7b
+88.31%
|
$1.7b
+3.44%
|
$1.5b
-12.26%
|
$1.4b
-10.13%
|
$1.3b
-8.30%
|
$1.8b
+44.72%
|
|
| Other Operating Income (Expense), Net | $751.2m | $1.1b | $0 | $0 | $897.6m | $1.7b | $1.7b | $1.5b | $300k | $67.2m | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($500k) | ($5.4m) | $6.7m | $5.9m | $12.3m | $5.0m | ($1.2m) | $10.5m | $7.1m | $700k | — | |
| Gain (Loss) on Investments | — | — | — | — | — | — | ($51.5m) | ($100k) | $5.2m | — | — | |
| Gain (Loss) Related to Litigation Settlement | $0 | — | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($4.9m) | ($8.2m) | $4.0m | $8.2m | $11.5m | $12.7m | $2.6m | $14.4m | $68.9m | $7.2m | — | |
| Interest Expense (non-operating) | $19.2m | $23.2m | $29.9m | $20.7m | $15.8m | $18.4m | $19.2m | $17.6m | $19.8m | $20.4m | $20.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $378.2m | $491.5m | $266.1m | $383.4m | $151.3m | $610.9m | $634.4m | $348.0m | $265.7m | ($157.5m) | $1.4b | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | $1.2b | $916.7m | $1.7b | $1.8b | $1.6b | $1.5b | $1.3b | $1.4b | |
| Current Income Tax Expense (Benefit) | $192.9m | $424.2m | $60.4m | $109.1m | $145.5m | $242.9m | $496.4m | $460.7m | $314.9m | $282.7m | $439.0m | |
| Income Tax Expense (Benefit) | $168.4m | $451.3m | $39.2m | $119.6m | $93.3m | $198.9m | $245.5m | $198.7m | $152.1m | $216.9m | $439.0m | |
| Net Income (Loss) Attributable to Parent | $569.5m |
$583.6m
+2.48%
|
$722.2m
+23.75%
|
$1.0b
+44.96%
|
$823.4m
-21.35%
|
$1.5b
+82.55%
|
$1.5b
+1.25%
|
$1.4b
-7.85%
|
$4.2b
+197.68%
|
$1.1b
-74.28%
|
$1.0b
-6.39%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | — | $0 | $0 | ($3.0m) | ($4.9m) | ($4.1m) | $1.0b | |
| Earnings Per Share, Basic | $0.89 | $0.92 | $1.15 | $1.68 | $1.32 | $2.41 | $2.46 | $2.31 | $6.98 | $1.84 | $1.74 | |
| Earnings Per Share, Diluted | $0.87 | $0.90 | $1.13 | $1.64 | $1.30 | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 | $1.72 | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | — | — | — | $2 | $2 | $2 | $2 | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | — | — | — | $2 | $2 | $2 | $2 | — | |
| Weighted Average Number of Shares Outstanding, Basic | 639.0m | 632.7m | 627.6m | 624.9m | 622.6m | 623.3m | 619.0m | 606.7m | 597.7m | 584.8m | 580.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | 653.4m | 647.7m | 640.8m | 636.6m | 631.9m | 631.2m | 624.2m | 609.4m | 599.3m | 585.8m | 581.5m | |
| Additional Financial Items | ||||||||||||
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | $700k | — | — | — | — | — | — | |
| Reclassification from AOCI, Current Period, before Tax, Attributable to Parent | — | — | — | $49.7m | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | $1.2b | $916.7m | $1.7b | $1.8b | $1.6b | $1.4b | $1.1b | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | $0 | $0 | $3.0m | $1.4b | $1.1b | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | $197.9m | $179.4m | $2.8b | $13.4m | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | $197.9m | $179.4m | $2.8b | $13.4m | — | |
| Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component | — | — | ($100k) | $200k | $400k | $300k | ($1.1m) | ($1.2m) | ($600k) | ($1.7m) | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.